MEDTECH LEADERS AGENDA
*** 17:40 - 20:00 Wednesday September 13 - Stay with us for the networking reception ***
Day 1 – Wednesday September 13
09:00 LSX Welcome Address
Caitlin McNally, Conference Director, LSX
09:15 Keynote Panel: Acquisition A-Game - Strategies For Securing Success
Despite global disruptions and slowdown in IPO and SPAC activity in 2022, the final quarter of the 2022 saw an increase in M&A deal-making in the medtech industry. Whilst not hitting the heights of previous years, industry financing remains robust for the right innovations, and the demographic shift and the growth in the consumer health sector is offering new opportunities for medtech companies. However, competition for funds and opportunities is fierce, making it crucial for medtech companies to develop sound business strategies and position themselves for long-term success. A panel of experienced medtech industry experts will discuss how medtech companies can bolster their M&A and business development strategies in 2024
Antonio Sánchez-Cordero, Vice President, Strategy & Business Development (M&A), Specialty Diagnostics Group, Thermofisher
Dan Wolf, SVP, Baxter
Christos Monovoukas, VP, Business Development and Strategy, Zimmer Biomet
Kristine Ilaria, VP of Corporate Development, Smith & Nephew
10:10 Fireside Chat: A Deal Well Done – M&A & Strategic Partnerships
Saurabh Bhasin, SVP Corporate Development M&A, Fresenius Kabi
Jørgen Bundgaard Hansen, Former CEO, Ivenix
10:30 Morning Break
11:00 Keynote Panel: Diagnostic Disruption - The Evolving Landscape Of Medtech Diagnostics
The American healthcare system, with among the world’s highest healthcare costs, continually focusses heavily on reactive treatment. With successive and concurrent crises, there is a need more than ever before, for proactive diagnostic and preventative care. With the IVD sector tipped as the largest device area by 2028, coupled with the digital transformation of the industry, the opportunity in this sector is ever-growing. A panel of diagnostic industry leaders discuss how medtech companies can tap into this sectors growth and how to traverse potential obstacles.
12:00 Panel: Global Market Access - The Medtech Maze Across Europe, US, And China
The global medtech market access landscape presents a complex maze for companies to navigate. With globally unique requirements and regulations in a rapidly evolving industry, knowing where to start can be a challenge in itself. A panel of market access leaders discuss the differing paths to market worldwide, their unique challenges and opportunities and how medtech companies can best position themselves to get their product to the payer.
12:45 Lunch Break
Jonathan Gertler, Managing Director, BioVentures MedTech Funds
David Kereiakes, Partner, Providence Ventures
Daniel Gottlieb, Associate Director, Broadview Ventures
15:30 Afternoon Break
17:40 Drinks Reception
Day 2 – Thursday, September 13
09:00 LSX Welcome Address
09:15 Keynote Panel: Medtech Evolution: Harnessing The Power Of Innovation For A Better Healthcare System
The innovation environment is rapidly evolving and presents a wealth of opportunities for companies to make an impact. With a massive pipeline of technologies, there is an abundance of potential for new and exciting products to be developed. However, with this potential comes challenge, including the need for end-to-end solutions, incorporating the voice of the clinician, and providing not just the product but the training to use it. Even before prototyping, there is a need to consider how hospitals will adopt the product, including buying, storing and reimbursement codes, as well as the explosion of data and the risk of clinician burnout. The industry is at a turning point, and those who can navigate these challenges will be well-positioned to make a real difference in the healthcare system. A panel of industry leaders discuss how medtech companies need to companies can succeed in an increasingly saturated market.
10:15 Morning Break
11:00 Panel: Green And Clean – Why ESG Should Be A Priority
Medtech companies are facing a growing emphasis on Environmental, Social, and Governance (ESG) considerations, as investors and stakeholders look for companies with a strong commitment to sustainability, social responsibility, and ethical practices. However, companies face unique challenges in implementing such policies, when balancing these commitments with regulatory compliance and high R&D costs. Despite these challenges, medtech companies that prioritise ESG considerations can reap benefits such as cost reduction, improved reputation, and talent attraction. As healthcare shifts towards value-based care, companies with strong ESG practices will be well-positioned to meet the needs of health-conscious consumers. A panel of industry leaders discuss why medtech CEO’s should push ESG policies up their priority list.
12:00 Panel: CVC Collaboration - Building Winning Partnerships
As the medtech industry continues to evolve and innovation becomes increasingly important, many small and medium-sized medtech companies are turning to corporate venture capital (CVC) as a source of funding and strategic support. CVC allows these companies to tap into the resources and expertise of larger, established players in the industry, while also providing an opportunity for these larger companies to access new technologies and business models. However, for medtech companies, navigating the CVC landscape can be tricky. This panel will bring together industry experts to discuss the role of CVC in the medtech industry and provide insights on what medtech companies need to know in order to be successful in securing CVC funding.
Oliver Keown, Managing Partner, Intuitive Ventures
Lana Caron, Sr Director, Philips Ventures
Kadir Kadhiresan, VP, Venture Investments, Johnson & Johnson Innovation
Alex de Winter, Vice President of New Ventures, Danaher Ventures
13:00 Lunch Break
14:00 Panel: Chain Reaction - Keeping The Medtech Industry's Supply Chain On Track
Being a sector heavily reliant on complex global supply chains, disrupted by a variety of factors, including natural disasters, geopolitical tensions, and trade disputes, there is pressure for companies to increase their agility. Additionally, as the industry becomes more digitized and data-driven, there is an increased need for secure and reliable data management and communication throughout the supply chain. Industry leaders are now investing in strategies to improve supply chain resilience, such as diversifying suppliers and implementing real-time data analytics. A panel of industry leaders discuss how companies can increase their supply chain resiliency.
14:40 Panel: Designed To Last – Developing Future-Proof Innovations
Although producing essential products and somewhat shielded with what the economy can throw at them, medtech companies are facing an increasingly oversaturated market. Companies need to have data-driven strategies and technologies in place to demonstrate their value to investors, clients, and regulators. These macroeconomic factors coupled with a shifting healthcare system and increasing digital transformation requires companies to shift their thinking on product design and manufacturing to build recurrent revenue streams and ensure true value for their customers. Key leaders in product design and development discuss considerations and potential challenges for companies taking their product off the page and into the market.
15:20 Closing Keynote Panel: Health Equity – Confronting Racial Bias, Promoting Inclusion And Improving Diversity
Racial bias, lack of inclusion and diversity in the medtech industry is a critical issue that negatively impacts patient care and outcomes. Research in women’s health, and studies inclusive of minority populations has been historically neglected. This is demonstrated in historical lack of funding in these areas, the use of biased data and AI models which inaccurately reflecting the needs and experiences of diverse patient populations. This results in suboptimal care and unequal healthcare outcomes for women and minority populations. Key thought leaders discuss how the current medtech industry is and isn’t addressing health inequities and how medtech companies can bridge the gap.
16:00 Close of Congress
Showcasing all stages of private & public biotech, healthtech & medtech
2022 showcasing companies included:
Day 1–Wednesday 13 September - 13:45
The Medtech CEO Forum provides a unique, powerful and valuable space for the candid sharing of ideas and experience between executives from 25-20 of the sector's leading medical device and diagnostics companies.
The forum is designed to foster new ideas and create new relationships between attendees so that they can leave with tangible outcomes and that will drive their businesses and the sector forward.
The forum features 3 x interactive peer review case studies of recent transactions, deals, milestones, or company growth stories which are presented by CEOs or event partners, followed by Q&A and general discussion.
Open to CEO, Founder, Co-Founder, President, Chairman or c-suite executive (CFO, CBO, CCO, CSO, CMO) of medtech companies.
Free to attend, pre-registration only, Chatham House Rule forum where all participants are active discussants.
Benchmark yourself against your peers
Uncover key factors of success
Share war stories and common challenges
Engage in peer-to-peer discussion
Make meaningful connections
Find new ways to help your business thrive